Hi all. Quick question for anyone happy to answer.
I'm inclined to agree with those of you who say Neuren is undervalued at current levels and that the market isn't pricing in the potential of NNZ-2591. However if we see that this phase 3 trial experiences setbacks or for arguments sake, is unsuccessful: is it unreasonable to think the share price will be punished, even in the long term? I can't help but suspect that now, the market IS pricing in NNZ-2591 to some extent, but happy to be proved wrong.
Any and all thoughts are greatly appreciated.
Cheers.
Hi all. Quick question for anyone happy to answer. I'm inclined...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$20.48 |
Change
0.500(2.50%) |
Mkt cap ! $2.586B | |||
| Open | High | Low | Value | Volume |
| $20.10 | $20.53 | $19.95 | $14.61M | 718.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2545 | $20.34 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $20.48 | 2029 | 1 |
View Market Depth
| Last trade - 16.10pm 05/09/2025 (20 minute delay) ? |
| NEU (ASX) Chart |